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ABSTRACT
Previous studies on macrolide resistance in Campylobacter were primarily
focused on the isolates from various origins using in vitro systems. In this study, both in
vitro and in vivo experiments were conducted to examine the development, stability, and
genetic basis of macrolide resistance in C. jejuni. All in vitro and in vivo selected EryR
mutants were derived from the same parent strain C. jejuni NCTC 11168. To determine if
long-term exposure of low-level EryR C. jejuni to low-dose tylosin selects for high-level
EryR mutants (MIC > 512 µg/ml), two low-level EryR mutants (MIC = 32 or 64 µg/ml)
were used to inoculate chickens at 15 days of age in two independent experiments. Total
and EryR C. jejuni populations in swabs collected at different time points were
determined by differential plating and MIC test. The in vitro stability was tested by
repeated subculturing of EryR mutants in Ery-free broth medium. The in vivo stability
was tested by inoculating 3-day-old chickens (12-13 birds/group) receiving nonmedicated feed with EryR mutants and collecting cloacal swabs from each chickens at 12,
22, 38, and 47 days of age. Total and EryR C. jejuni populations in culture (after 10, 20
and 33 passages) or swab were determined by differential plating and MIC test. Genomic
DNA from each of 63 selected EryR mutants was used for PCR amplification and
sequence analysis of 23S rRNA gene and ribosomal proteins L4 and L22. Mutation in
CmeABC multidrug efflux pump was transferred to EryR strains to determine the role of
CmeABC efflux pump in Ery resistance. Chicken studies showed that the length of
exposure time to subtherapeutic level of tylosin is not a sole factor contributing to the
emergence of highly EryR Campylobacter. Prolonged exposure of low-level EryR C.
jejuni (MIC = 32 or 64 µg/ml) to tylosin did not select for highly EryR mutants. The lowiv

level Ery resistance (MIC = 32μg/ml) was stable after 10 passages in vitro but majority of
C. jejuni were sensitive to Ery after 20 passages. The instability of low-level Ery
resistance was also observed in chickens as early as 9 days postinoculation and EryR
mutants were rarely isolated 35 days postinoculation. However, high-level Ery resistance
(MIC > 512μg/ml) displayed remarkably stability in vitro and in vivo. All high-level EryR
mutants selected in vivo displayed the A2074G mutation in 23S rRNA gene, distinct from
the specific mutation (A2074C) observed in all highly EryR mutants selected in vitro. No
mutations were observed in ribosomal proteins L4 for all in vitro selected EryR mutants
but specific mutations in L4 (G74D or G57D) were widely found in low level EryR
mutants selected in vivo (Ery MIC = 8-64 μg/ml). Insertion of three amino acids TSH at
position 98 in L22 was only observed in mutants selected in vitro with Ery MIC ranging
from 32-512 μg/ml. The CmeABC efflux pump worked synergistically with other
mechanisms to confer Ery resistance in C. jejuni. Together, these findings indicated that
C. jejuni utilize complex and different mechanisms to develop Ery resistance in vitro and
in vivo.
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1. REVIEW OF LITERATURE

Animal antibiotic use and antibiotic resistance in foodborne pathogens
The intensity of food animal production systems presents opportunities for the
introduction and spread of disease. Therefore, antibiotics are often administered to food
animals to improve health and growth performance. According to a recent estimate, 24.6
million pounds, over half of the antibiotics produced each year in the US, are used in
agriculture (Mellon et al. 2001). In animal agriculture, antibiotics can be administered
whenever symptoms appear in a few animals (therapeutic treatment), or in anticipation of
symptoms (prophylactic treatment). In addition, some antibiotics are widely administered
as feed additives at sub-therapeutic levels in food animals to enhance growth rates and
improve feed efficiency (growth promotion) (Dibner & Richards 2005; Frost &
Woolcock 1991). The antibiotics used for growth promotion are also called ‘antibiotic
growth promoter’ (AGP) and have been used worldwide in food animals more than 50
years (Dibner & Richards 2005; Frost & Woolcock 1991). To date, many antimicrobials
with different mechanisms of action have been used as AGPs in the food animal industry
(Chapman & Johnson 2002; Frost & Woolcock 1991; Gaskins et al. 2002). In poultry,
antibiotics including bacitracin, virginiamycin, tylosin, bambermycins, and lincomycin
have been used as AGPs with no withdrawal period required (Animal Health Institute
2005; Chapman & Johnson 2002; Gaskins et al. 2002). Usually a combination of
different AGPs instead of single AGP is used in feeds during a complete production cycle
to maximize the efficacy of AGPs. In poultry, bacitracin was used more frequently than
other antibiotics in the starter and grower feed while virginiamycin was used more
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frequently in finisher feed (Chapman & Johnson 2002).
Foodborne human pathogens are increasingly resistant to antimicrobial agents,
compromising the effectiveness of currently available drugs for treating human illness
(White et al. 2002). Development of antimicrobial resistance in bacteria may also
directly affect human disease development through various mechanisms such as
increased virulence (Barza 2002). One of the driving forces behind the progression of
antibiotic resistance is the selective pressure exerted by the widespread use of
antimicrobial agents in food animal production (Teuber 1999; Wegener 2003a).
Inappropriate use of antibiotics in agriculture can result in increased antibiotic-resistant
organisms, not only among pathogens but also among commensal microflora of animals
that can be subsequently transferred to human via the food chain (McEwen & FedorkaCray 2002; Wegener et al. 1997). This possibility is particularly strong with foodborne
human pathogens, such as Campylobacter and Salmonella, which are primarily
transmitted from animals to humans via contaminated food (Slutsker et al. 1998). Since
person-to-person transmission rarely occurs with these foodborne human pathogens in
developed countries, the primary sources of human infections with resistant bacteria are
likely from food producing animals (White et al. 2002). Therefore, food animals can
serve as a reservoir for resistant bacteria (Witte 2000) and/or resistant gene clusters
which can then enter the environment and be transmitted to human pathogens (Heuer et
al. 2006; Lipsitch et al. 2002).
Therapeutic use of antibiotics has been demonstrated to select drug resistant
human pathogens in food animals (Aarestrup 2005; Angulo et al. 2004). Recent studies
have shown an increase in Campylobacter resistance to fluoroquinolones (FQs), a drug of
2

choice for treating human infections, following the approval of FQs for treatment of food
animal infections in 1995 (Gaudreau & Gilbert 2003; Hein et al. 2003; Nachamkin et al.
2002). Laboratories studies have demonstrated the emergence of FQ-resistant
Campylobacter in experimental chickens (Luo et al. 2003; McDermott et al. 2002) and
pigs (Delsol et al. 2004) treated with FQ antibiotics. Strikingly, FQ treatment of chickens
infected with FQ-sensitive Campylobacter promoted the emergence of FQ-resistant
Campylobacter mutants; almost all Campylobacter shed by chickens were FQ-resistant
after just 3 days of enrofloxacin treatment (Luo et al. 2003). These findings highlight the
need for the prudent use of FQ antibiotics. Consequently, to prevent and control
Campylobacter resistance to FQs, the FDA issued a ban on the use of Baytril (a FQ used
in animal) in poultry in 2005 ( www.fda.gov/bbs/topics/news/2005/new01212.html).
Evidence of an association between the use of gentamicin in food animals and gentamicin
resistant Enterococci isolated from food of animal origin and humans was also recently
reported. Resistant rates of more than 30% were reported on swine and poultry farms in
Michigan, Wisconsin, and Indiana (Hershberger et al. 2005). The same gentamicin
resistance genes present in Enterococci isolated from food animals were also found in
isolates from food products of the same animal species (Donabedian et al. 2003).
Although it has been widely believed that the low dosages of AGP used for
growth promotion are an unquantified hazard, long-term use of AGP in feed could exert
great selection pressure for developing antibiotic-resistant bacteria (WHO, 2004)
Epidemiological studies have strongly linked AGP application to the emergence of
antibiotic-resistant bacteria, consequently posing a serious threat to public health
(Wegener 2003a). For example, vancomycin resistant Enterococci have long been
3

associated with the use of avoparcin (a vancomycin analogue) as growth promoters in
food animals (Bager et al. 1997; Wegener et al. 1999) Thus, Denmark banned all AGPs
in 1998 and European Union member nations banned all AGPs in January 2006 (Dibner
& Richards 2005; Wegener 2003b). However, in Europe, it has been observed that the
levels of antibiotic resistance in animals and food, and consequently in humans, have
been markedly reduced after the termination of AGP use (Wegener 2003b). In
Switzerland, Boerlin et al. (2001) reported a clear decrease in Enterococci resistance to
macrolides, lincosamides, and tetracycline after the ban of AGPs. In Tawain, the
occurrence of vancomycin resistant Enterococci decreased in association with a ban on
avoparcin as a feed additive on chicken farms (Lauderdale et al. 2007). Other studies also
noted a decrease in vancomycin- resistant enterococci following the ban on avoparcin as
a growth promoter, although the resistant strains did not disappear completely
(Heuer et al. 2002; Borgen et al. 2001). Furthermore, several studies have also noted a
reduction of vancomycin resistant Enterococci in food-animal products and humans
following AGP ban in food animals (Klare et al. 1999; van den Bogaard et al. 2000;
Witte 2000; Bager et al. 1999; Pantosti et al. 1999). Together, these findings provide
compelling evidence for the role of AGPs in selecting resistant bacteria. Using
experimental chicken model system, Lin et al. (2007) demonstrated that long-term use of
a macrolide as a growth promoter selects for the emergence of erythromycin-resistant
Campylobacter in animal reservoirs. However, chickens subjected to single or multiple
treatments with therapeutic dose of macrolide did not select for erythromycin-resistant
Campylobacter (Lin et al. 2007).
There is a worldwide trend of limiting AGP use in food animals (Dibner &
4

Richards 2005). Although there has been little regulatory activity regarding AGP use in
the United States, consumer pressure, market limitations, and export restrictions are
pressuring commerce to withdraw AGPs from market (Dibner & Richards 2005). For
example, KFC and McDonalds have claimed that they do not accept chicken meat grown
using AGP with similar structure to the antibiotics used in humans in 2002 and 2005,
respectively (Dibner & Richards 2005b).

Campylobacter colonization in poultry
Campylobacter species are the most common cause of human gastrointestinal
enteritis worldwide, accounting for 2.5 million cases each year in the United States
(Friedman et al. 2000). Each year in the United States, 1.5 to 8 billion dollars in medical
and production costs are attributed to Campylobacter infections (Buzby et al. 1997).
Human Campylobacter infections are characterized by abdominal pain, watery or bloody
diarrhea lasting a few days, and also fever, headache, nausea, and vomiting (Skirrow &
Blaser 2000). The diarrhea typically lasts a few days. Although complications are rare,
infection with Campylobacter can lead to Guillain- Barré syndrome an acute autoimmune
disease affecting the peripheral nervous system that can result in respiratory compromise
and death (Nachamkin et al. 1998). Human Campylobacter illness is caused primarily by
C. jejuni and secondarily by C. coli. Both Campylobacter species are closely related and
require microaerophilic conditions (e.g. 5% O2, 10%CO2, and 85% N2) and elevated
temperature (42 oC) for optimal growth.
Although Campylobacter widely colonizes wild and domestic animals, poultry are
considered the major reservoir of Campylobacter (Nesbit et al. 2001). Campylobacter is
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highly prevalent in poultry and most human infections have been linked to consumption
of undercooked poultry products or other food contaminated by these products (Allos
2001). Other sources of human contamination include raw milk, undercooked beef or
pork, and house pets (Corry & Atabay 2001). Interestingly, chickens mainly harbor C.
jejuni, while turkeys tend to have more C. coli. Despite wide prevalence of
Campylobacter in poultry, this organisms does not cause clinical signs of infection in
poultry host under natural conditions (Newell & Fearnley 2003; Sahin et al. 2002).
Although prevalence estimates of Campylobacter vary, recent studies showed that
80- 100% of broiler flocks in the US were contaminated with C. jejuni (Croft et al. 2007;
Jacobs- Reitsma 1997; Stern et al. 2001b). Campylobacter is highly prevalent in organic,
free-range, and conventional poultry production systems (Avrain et al. 2003; Heuer et al.
2001; Luangtongkum et al. 2006; Luangtongkum et al. 2006), indicating that different
production systems are equally vulnerable to invasion by this organism. The seasonality
of Campylobacter infections, with a peak in the summer months, is also well documented
(Evans & Sayers 2000; Sahin et al. 2002; Wedderkopp et al. 2000; Wedderkopp et al.
2001; Newell & Wagenaar 2000).
The prevalence of Campylobacter in broiler flocks depends on the age of the birds
(Evans & Sayers 2000; Newell & Fearnley 2003). In commercial conditions,
Campylobacter is rarely detected in broilers less than 2- 3 weeks of age (Stern et al.
2001a; Evans & Sayers 2000), although experimental inoculation of newly hatched
chicks with Campylobacter can establish colonization successfully (Sahin et al. 2003b;
Young et al. 1999). The reasons for this lag phase are unknown but might be attributed to
multiple factors, such as presence of maternal antibodies, antibiotic feed additives,
6

intestinal development, and intestinal microbial flora (Newell & Wagenaar 2000; Sahin et
al. 2003b).
Although Campylobacter can be isolated from most intestinal sites of broiler
chickens, it is mainly found in the cecal and cloacal crypts where it does not adhere to
epithelial cells but is found in the mucous layer (Achen et al. 1998; Beery et al. 1988).
While more than one strain of Campylobacter has been isolated from the same flock
(Hiett et al. 2002b), individual chickens are rarely infected with more than one strain
(Korolik et al. 1998). Experimental inoculation of chickens has shown that colonization
rate can be influenced by dose of inoculum and route of challenge (Sahin et al. 2002).
Once the first bird in a flock becomes colonized, infection spreads to the entire
flock in just a few days. This rapid spread of Campylobacter throughout the flock is
likely a result of fecal-oral transmission, compounded by communal water and feed (Lee
& Newell 2006). In broiler chickens, colonization persists for the lifetime of the animal
that is usually less than 47 days, consequently leading to carcass contamination at the
slaughter facility.
Although the sources of infection of poultry flocks are still unclear, horizontal
transmission (transmission within a population) is considered the most likely mechanism
(Sahin et al. 2002). Some potential sources include feed, water, and carryover from
previous flocks (Newell & Fearnley 2003). Campylobacter also exists in the environment
surrounding the broiler house and could be transferred into the house by wildlife species,
houseflies, insects, equipment, and farm workers (Sahin et al. 2002). However, molecular
typing of Campylobacter isolates from various sources including broilers, houses,
humans, and the environment surrounding the broiler house did not clearly identify the
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sources of Campylobacter (Nesbit et al. 2001; Petersen et al. 2001a). Campylobacter is
generally unable to persist in feed or water due to the stringent growing conditions
(Jacobs- Reitsma 2000; Van De Giessen et al. 1998). Litter is also a potential but unlikely
source of transmission (Stern et al. 2001b). Vertical transmission, although unlikely, has
been suggested as a source of Campylobacter infection in broiler flocks. The 2-3 week
lag phase presents evidence against vertical transmission. Also, broiler flocks are often
infected with different strains than the corresponding breeder flocks (Petersen et al.
2001b). Campylobacter has not been found in hatcheries or young hatchlings, and
isolation from eggs has also proven difficult (Hiett et al. 2002a; Sahin et al. 2003a).

Antibiotic resistance in Campylobacter
Most human Campylobacter infections are self-limited and treated with fluid
replacement (Allos 2001). However, antimicrobial treatment is often necessary for severe,
prolonged, or systemic infections, or infections in immunocompromised patients
(Engberg et al. 2001). In the US and other developed countries, Campylobacter isolates
resistant to multiple drugs have been cultured from clinical and food samples (Boonmar
et al. 2007; Gallay et al. 2007; Moore et al. 2005). Campylobacter isolates are
increasingly resistant to FQs and macrolides, the major drugs of choice for treating
human campylobacteriosis (Engberg 2006; Friedman et al. 2000; Moore et al. 2005;
Smith et al. 2002; van den Bogaard et al. 2000). Campylobacter could also acquire
resistance to other antibiotics such as tetracycline, β lactam, chloramphenicol, and
aminoglycosides (Trieber & Taylor 2000). Campylobacter species display intrinsic
resistance to rifampin and trimethoprim (Trieber & Taylor 2000). Thus, these two
8

antibiotics are included as selective agents in Campylobacter- specific growth
supplement (SR0117E; Oxoid). Campylobacter develops three general mechanisms of
antibiotic resistance: 1) inactivation of antibiotic itself (e.g. acetylation of
chloramphenicol) 2) target site alteration ( e.g. mutations in ribosome affecting macrolide
binding) 3) active drug efflux (e.g. CmeABC multidrug efflux pump) (Trieber & Taylor
2000).
Fluoroquinolones inhibit the activity of DNA gyrase and/ or DNA topoisomerase
IV in bacteria (Drlica & Zhao 1997). There are two general mechanisms for
Campylobacter resistance to FQs; which include modification of DNA gyrase and active
efflux (Luo et al. 2003; Zhang et al. 2003). Specific mutations such as Asp-90-Asn and
Thr-86-Lys in gyrase A were linked to FQ resistance in C. jejuni (Luo et al. 2003; Zhang
et al. 2003). Unlike other bacteria, acquisition of high-level FQ resistance in
Campylobacter does not require stepwise accumulation of point mutations in gyrA.
Instead, a single step mutation in gyrA can create clinically relevant levels of resistance
to FQs (Luo et al. 2003; Zhang et al. 2003). The simplicity of the gyrA-mediated
resistance mechanism may facilitate the rapid emergence of FQ-resistant Campylobacter
in response to FQ treatment (Zhang et al. 2003). It is still not clear why C. jejuni displays
a hypermutable phenotype and FQ- resistant mutants emerge rapidly in infected chickens
under the selective pressure of FQ antibiotics. A recent study indicated that the adaptive
gene expression in Campylobacter may contribute to the rapid emergence of FQ-resistant
mutants (Han & Zhang 2007). A multidrug efflux pump, named CmeABC, in
Campylobacter contributes to both intrinsic and acquired FQ resistance in clinical
isolates (Lin et al. 2002; Luo et al. 2003; Zhang et al. 2003). CmeABC is constitutively
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expressed in Campylobacter and is essential for maintaining high-level FQ resistance.
However, over-expression of CmeABC is not required for conferring the resistance,
which distinguishes Campylobacter from other Gram-negative bacteria. Increasing
resistance of Campylobacter isolates to FQs is associated with FQ usage in animals
(Aarestrup & Wegener 1999; Nielsen et al. 2006; Smith et al. 2002). Regarding in vivo
development of FQ resistance in Campylobacter, recent studies using chicken and pig
models showed that FQ treatment has resulted in rapid emergence of FQ-resistant
Campylobacter isolates (Delsol et al. 2004; McDermott et al. 2002; Luo et al. 2003).
Particularly, Luo et al. (2003) noticed that after just 3 days of treatment with enrofloxacin
(a quinolone antibiotic), 100% of Campylobacter shed by chickens were FQ-resistant. FQ
resistance in Campylobacter has been shown to be stable even after treatment has stopped
(McDermott et al. 2002; Luo et al. 2005).
Increased Campylobacter resistance to FQs has resulted in a decrease of FQ usage
in clinics. Erythromycin (a macrolide antibiotic) has become the best and a major choice
for treating human Campylobacter infections recently (Nachamkin et al. 2000). However,
an increase in Campylobacter resistance to macrolides in human and animal isolates has
been documented recently, arising more rapidly in developed countries (Gibreel & Taylor
2006). More detailed information regarding macrolide resistance in Campylobacter is
described below.

Macrolide resistance in Campylobacter
Macrolide antibiotics are the metabolic products of Steptomyces spp., which
inhibit bacterial protein synthesis by binding to the 50S subunit of ribosome (Walsh
10

2003). This class of antibiotics including erythromycin, tylosin, spiramycin, tilmicosin,
roxithromycin are approved for both growth promotion and therapeutic purpose in animal
agriculture in the US (Mcewen & Fedorka-Cray 2002).
The use of macrolides in food animals has been associated with resistance in
Campylobacter and presents opportunity for resistant isolates to reach humans via direct
or indirect contact with contaminated food products (Aarestrup 2000; Gibreel & Taylor
2006). The reported macrolide resistance rates vary with Campylobacter species and the
animal hosts. Campylobacter coli usually has higher macrolide resistance rates than C.
jejuni, regardless of the source of isolation (Aarestrup & Engberg 2001; Engberg et al.
2001; Kim et al. 2006). Likewise, pigs and turkeys tend to harbor higher numbers of
macrolide resistant Campylobacter than other animal species. For example, in a study
involving human, chicken, and pig isolates, C. coli was more resistant to Ery and
ciprofloxacin than C. jejuni (Gallay et al. 2007). C. coli isolated from retail raw meats
also showed higher rates of resistance to Ery and ciprofloxacin (Ge et al. 2003). In
Denmark, withdrawal of tylosin from swine feed additives significantly reduced EryR
Campylobacter in pigs (Boerlin et al. 2001). A study examining EryR Campylobacter
from broilers in France, before and after the growth promoter ban (1998), found no
difference in resistance rates in C. jejuni, while a higher number of resistant C. coli were
isolated after the ban. It is possible that the sample period was too close to the ban to
detect true differences (Desmonts et al. 2004). A high prevalence of Campylobacter has
been shown in poultry from both organic and conventional production operations, while
Campylobacter isolated from conventional poultry operations had significantly higher
resistance rates to FQs, Ery, clindamycin, kanamycin, tetracycline, and ampicillin than
11

Campylobacter isolated from organically raised poultry (Luangtongkum et al. 2006).
While EryR Campylobacter have been isolated from organically and intensively reared
retail poultry, the isolates with the highest Ery MIC values were from intensively reared
retail poultry (Soonthornchaikul et al. 2006). These observations suggest that different
production practices influence the frequency of macrolide-resistant Campylobacter in
animal reservoirs.
Direct experimental information supporting the relevance of macrolide use in
food animals with emergence of macrolide resistant Campylobacter is very limited. A
recent study found that long-term exposure of chickens to tylosin as a growth promoter
selected for EryR Campylobacter mutants, while short-term (therapeutic) exposure did
not (Lin et al. 2007). In this study, chickens experimentally infected with a macrolidesensitive Campylobacter strain were exposed to single or multiple therapeutic treatments
of tylosin in water or exposed to tylosin in feed as a growth promoter. However, EryR
mutants were not isolated from chickens receiving therapeutic tylosin treatment. In
contrast, EryR mutants were isolated from chickens after 17 days of exposure to tylosin
supplemented in feed as a growth promoter. In another recent study, Berrang et al (2007)
isolated Campylobacter from carcasses of chickens that received feed supplemented with
tylosin or unmedicated feed. Although the feed treatment did not affect actual numbers of
Campylobacter on carcasses after washing, carcasses from chickens fed tylosin in feed as
a growth promoter were found to harbor EryR Campylobacter, while carcasses from
chickens fed unmedicated feed were not. The information from these studies suggests
that use of tylosin as a growth promoter in feed results in EryR Campylobacter.
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Mechanisms of macrolide resistance in Campylobacter
Macrolide antibiotics inhibit bacterial growth by binding to the ribosome,
inhibiting protein synthesis by causing premature dissociation of the growing peptidyl
tRNA (Corcoran et al. 2006; Franceschi et al. 2004). Macrolide resistance in bacteria is
attributed to many mechanisms including target modifications (e.g. methylation of 23S
rDNA, point mutations in 23S rDNA, and mutations in ribosomal proteins), and drug
efflux (Gibreel & Taylor 2006). In Campylobacter, methylation of 23S rDNA is not
reported to confer macrolide resistance. Modifications of the ribosomal target site (e.g.
23S rDNA and ribosomal proteins L4 and L22) and active efflux (e.g. CmeABC efflux
pump) are major mechanisms conferring macrolide resistance in Campylobacter. (Gibreel
& Taylor 2006; Lin et al. 2002; Payot et al. 2006; Franceschi et al. 2004).
Resistance in C. coli and C. jejuni has been associated with mutations in domain
V of the 23S rRNA gene (Engberg et al. 2001; Gibreel & Taylor 2006; Mamelli et al.
2005). These point mutations within the 23S rRNA gene occur at base position 2074
(A2074C, A2074G, or A2074T) or 2075 (A2075G or A2075C), or both (which
correspond to positions 2058 and 2059, respectively, in E. coli) (Gibreel et al. 2005;
Jensen & Aarestrup 2001). There are three copies of the 23S rRNA gene in C. jejuni and
C. coli (Parkhill et al. 2000) and wild-type and mutant copies can both be present in a
single macrolide-resistant mutant (Gibreel et al. 2005). The most common mutation in
macrolide-resistant Campylobacter is A2075G, which is associated with high-level
erythromycin resistance (Gibreel & Taylor 2006). The A2074G mutation also confers
high-level resistance but was thought to negatively affect the fitness of the organism, and
was relatively unstable (Gibreel et al. 2005). Recently, all high- level erythromycin13

resistant Campylobacter mutants selected in vivo displayed the A2074G mutation in the
23S rRNA gene (Lin et al. 2007).
Mutations in ribosomal proteins L4 and L22 have been reported to be associated
with Ery resistance in Campylobacter (Corcoran et al. 2006). Gibreel et al (2005) did not
find significant macrolide resistance-associated alterations in either L4 or L22 protein
from five erythromycin-resistant clinical isolates. However, the involvement of some
modifications in ribosomal proteins L4 and L22 in conferring macrolide resistance in
Campylobacter has recently been demonstrated. A G74D mutation in protein L4 and
insertions in protein L22 (ins86ARAR and ins98TSH) contributed to macrolide resistance
(Cagliero et al. 2006b). Further investigations of modifications in these proteins are
necessary to determine the exact effects of specific mutations on resistance.
The CmeABC efflux pump has been well documented as the major drug efflux
pump in Campylobacter (Lin et al. 2002; Luo et al. 2003). This pump has action against
a variety of compounds (Gibreel & Taylor 2006). In the presence of efflux pump
inhibitor, Campylobacter isolates displayed increased susceptibility to bile salts and
reduced colonization in chickens (Lin et al. 2003; Lin & Martinez 2006). CmeABC
efflux pump could play an important role in conferring macrolide resistance in
Campylobacter (Cagliero et al. 2006b; Lin et al. 2002; Payot et al. 2004). Inhibition of
the efflux pump has resulted in increased susceptibility to macrolides (Cagliero et al.
2006b; Cagliero et al. 2006a; Corcoran et al. 2006; Lin et al. 2007; Payot et al. 2004),
reducing both intrinsic and acquired resistance. Mamelli et al. noticed that low-level
macrolide resistant isolates were susceptible to efflux pump inhibitor. The antibioticsusceptible wild-type strain also showed increased susceptibility upon inhibition of the
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efflux pump (Mamelli et al. 2005). The CmeABC efflux pump works in synergy with
mutations in 23S rRNA and inactivation of the pump has resulted in increased
susceptibility of high-level and low-level resistant human, pig, and poultry
Campylobacter isolates to erythomycin (Cagliero et al. 2005; Lin et al. 2002, 2007).

Fitness and stability of antibiotic resistant Campylobacter
The ecological fitness and stability of the antimicrobial resistance is a key
parameter influencing the incidence, transmission, and persistence of antibiotic resistant
bacteria in humans and in animal reservoirs (Andersson 2006). Acquiring drug resistance
usually incurs a fitness cost in bacteria (Andersson & Levin 1999; Andersson 2003;
Bjorkman & Andersson 2000; Gillespie 2001; Kanai et al. 2004; Levin et al. 2000;
Maisnier-Patin & Andersson 2004; Normark & Normark 2002; Sander et al. 2002).
Antibiotic-resistant bacteria frequently acquire compensatory mutations to avoid a fitness
cost and maintain competitiveness with parent sensitive strains (Andersson 2006).
However, some resistance-conferring mutations in bacteria incur very little fitness cost,
none at all, or even enhanced fitness (Luo et al. 2005; Sander et al. 2002; Spratt 1996).
Using delicately designed experiments, Luo et al. (2005) recently demonstrated
that the FQ-resistant Campylobacter do not show a fitness cost in vivo and are
ecologically competitive in the colonization of chickens even in the absence of antibiotic
selection pressure. When separately inoculated into chickens, sensitive and resistant
strains, derived from the same parent strain, showed similar levels of colonization. The
resistance was persistent throughout this colonization. However, when both strains were
co-inoculated into the same chicken host, the resistant strain was able to outcompete the
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sensitive strain. Specifically, when co-inoculated into chickens, the FQ-resistant strain
outcompeted the FQ-sensitive strain, completely replacing the FQ-sensitive strain in just
3 days, and the specific resistance-conferring mutation did not disappear after prolonged
colonization in vivo (Luo et al. 2005). This enhanced fitness was the result of a single
point mutation in gyrA, instead of compensatory mutations, as evidenced by similar
findings using isogenic gyrA mutants together with parent FQ-sensitive strain (Luo et al.
2005). Fluoroquinolone-resistant Campylobacter have been shown to be competitive
with FQ-sensitive strains in vivo, displaying similar levels of colonization.
Fluoroquinolone-resistant Campylobacter have been cultured from farms where FQ
usage had been discontinued (Luangtongkum et al. 2006; Pedersen & Wedderkopp 2003;
Price et al. 2005). Fluoroquinolone and macrolide- resistant Campylobacters were found
on organically and intensively-reared chickens purchased from retail outlets
(Soonthornchaikul et al. 2006). These results indicate that FQ resistance-conferring
mutations in Campylobacter are stable, and the resistant strains can persist even in the
absence of antibiotic selection pressure, presenting an unusual problem. Humans infected
with FQ-resistant Campylobacter have had prolonged diarrhea and hospitalization, and
increased risk of complications in comparison to humans infected with FQ-sensitive
Campylobacter (Nelson et al. 2004), and this might be attributed to increased virulence
resulting from enhanced fitness of the FQ-resistant Campylobacter. Other studies also
showed that in comparison with FQ-sensitive Campylobacter, infections with FQresistant Campylobacter have resulted in prolonged illness (Engberg et al. 2004) and
increased risk of adverse health events (invasive disease or death within 90 days) (Helms
et al. 2005).
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Little information exists concerning fitness cost and stability of macrolide
resistant Campylobacter. A recent study on the stability of erythromycin-resistant
Campylobacter with mutations in 23S rRNA gene (corresponding to E. coli numbers
A2059G, A2058C, and A2058G), revealed that the A2059G and A2058C mutations were
stable after 15, 35, and 55 passages on MH agar plates (Gibreel et al. 2005). Because
Campylobacter resistance to macrolides is on the rise, stability of macrolide resistance in
Campylobacter should be thoroughly investigated to develop effective farm-based
strategies to prevent and control emergence and transmission of EryR Campylobacter.
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2. INTRODUCTION

Campylobacter jejuni is recognized as a leading cause of human gastrointestinal
enteritis worldwide (Gibreel et al. 2005; Nachamkin et al. 2000). The majority of
Campylobacter infections involve diarrhea and abdominal pain, although Campylobacter
is also associated with Giullain- Barré syndrome, an acute demyelinating disease that can
result in respiratory compromise and death (Moore et al. 2005; Nachamkin et al. 1998).
In the United States, the estimated number of cases of campylobacteriosis exceed 2
million per year (Friedman et al. 2000; Mead et al. 1999). The medical and production
costs associated with Campylobacter infections are estimated at 1.5 to 8 billion dollars
each year in the United States (Buzby et al. 1997). Most cases of campylobacteriosis are
self- limiting, but antimicrobial treatment is often necessary for severe, prolonged, or
systemic cases, or cases in immunocompromised patients.
In parallel to its increased prevalence, Campylobacter is increasingly resistant to
antibiotics including Fluoroquinolone (FQ) and macrolide antibiotics, the drugs of choice
for treating human Campylobacter infections (Altekruse et al. 1999; Engberg et al.
2001). FQ antibiotics are losing their effects on Campylobacter because this pathogen has
become highly resistant to FQ’s. Therefore, erythromycin (Ery), a macrolide antibiotic,
has been considered the best choice for treating human Campylobacter infections (Allos
2001). Unfortunately, Campylobacter resistance to macrolides is also on the rise and this
class of antibiotics could eventually lose effectiveness against Campylobacter (Engberg
et al. 2001; Smith et al. 2007). To develop effective measures to control and prevent the
spread of macrolide-resistant Campylobacters, the mechanisms of macrolide resistance in
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Campylobacter are critical to understand, but still are not clear.
Campylobacter species colonize the intestinal tract of wild and domestic animals
(Nesbit et al. 2001). Most human Campylobacter infections are associated with
consumption of undercooked poultry meat, as well as unpasteurized milk and untreated
water (Friedman et al. 2000). Epidemiologic studies have revealed poultry as the major
reservoir of Campylobacter (Corry & Atabay 2001; Jacobs- Reitsma 1997). Macrolide
usage in food producing animals is considered to be a major factor influencing the
emergence of erythromycin-resistant (EryR) Campylobacter (Gibreel & Taylor 2006).
However, the direct impact of macrolide usage on erythromycin resistance development
has not been formally determined in experimental systems until recent examination on
the dynamics of Campylobacter populations in chickens treated with a tylosin, a
macrolide antibiotic (Lin et al. 2007). Exposure of chickens to therapeutic doses of
tylosin did not select for EryR mutants in the treated birds. However, when tylosin was
given to the chickens in feed at a growth-promoting dose, EryR mutants emerged in the
birds after prolonged exposure to the antibiotic (Lin et al 2007). Specifically, the
chickens inoculated with a sensitive C. jejuni strain at 17 days of age started to shed EryR
mutants on day after inoculation (DAI) 17 in response to long-term exposure to growth
promoter tylosin; but all EryR mutants only showed low-level Ery resistance with MIC
ranging from 8 to 16 µg/ml. Interestingly, when chickens were inoculated with the same
Ery sensitive C. jejuni strain at 3 days of age, EryR mutants were only detected in the
chickens on DAI 31 and 38 but not in chickens at DAI 17, and 24; majority of EryR
mutants displayed high-level Ery resistance (MIC > 512 µg/ml). Although these findings
provide compelling evidence that long-term use of macrolide as a growth promoter
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selects for the emergence of EryR Campylobacter in chickens, the length of exposure time
to macrolide seems not the only factor contributing to the emergence of Ery resistance in
Campylobacter.
The stability of the resistant phenotype is a key parameter influencing the
development and transmission of antibiotic resistance (Andersson 2006). In many
bacterial species, antibiotic resistance confers a reduction in bacterial fitness and thus
antibiotic resistance phenotype is not stable in the absence of antibiotic selection pressure
(Nachamkin et al. 2000). However, distinct from other bacteria, FQ resistance in
Campylobacter is very stable and FQ-resistant mutants do not show a fitness cost in vivo
and are ecologically competitive in the colonization of chickens even in the absence of
antibiotic selection pressure (Luo et al. 2005). The stability of Ery resistance in
Campylobacter is still largely unknown. To develop effective farm-based strategies to
prevent and control emergence and spread of Ery resistant Campylobacter, in vitro and in
vivo stability of EryR C. jejuni mutants with different levels of Ery resistance should be
thoroughly investigated.
Significant progress has been made in elucidating molecular mechanisms of
macrolide resistance in Campylobacter. Modifications of the ribosomal target site and
active efflux are the major mechanisms that confer Campylobacter resistance to
macrolides (Engberg et al. 2001; Trieber & Taylor 2000; Lin & Martinez 2006).
However, previous studies on the mechanisms of macrolide resistance in Campylobacter
either focused on the comparison of isolates from various origins or examined macrolide
resistant mutants selected in vitro, greatly limiting the interpretation of association of
specific molecular mechanisms with acquired Ery resistance and limiting elucidation of
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macrolide resistance development in vivo in Campylobacter (Cagliero et al. 2006b;
Mamelli et al. 2005). Examination of in vivo- as well as in vitro-selected macrolide
resistant mutants that are all derived from the same parent sensitive strain would greatly
improve our understanding on the molecular basis and development of macrolide
resistance in Campylobacter.
Based on this published information and our previous work on antibiotic
resistance in Campylobacter, we speculate that length of exposure to growth promoter
tylosin and other in vivo factors affect the dynamics of emergence of EryR
Campylobacter mutants. Different molecular mechanisms together contribute to the
stability and level of Ery resistance in C. jejuni. To test these hypotheses and move
towards the goal of controlling macrolide resistance in Campylobacter, we pursued the
following three specific objectives:
1. Determine if long-term exposure of low-level EryR C. jejuni to growth promoter
tylosin selects for high-level EryR mutants using chicken model system.
2. Determine in vitro and in vivo stability of the macrolide-resistant phenotype in
Campylobacter.
3. Determine the molecular mechanisms of macrolide resistance in C. jejuni mutants
selected in vitro and in vivo.
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3. MATERIALS AND METHODS

Bacterial Strains and Culture Conditions
The key C. jejuni strains used in this study are listed in Table 1. Campylobacter
jejuni NCTC 11168 is an Ery-sensitive strain whose whole genome sequence has been
completed and published (Parkhill et al. 2000). NCTC 11168 was purchased from ATCC
(Cat. No 700819). The NCTC 11168 was used as a parent strain for in vitro selection of
macrolide resistant mutants in this study. The NCTC 11168-derived EryR mutants
isolated from chickens (Lin et al. 2007) were also used in this study. All Campylobacter
strains used were cultured in Mueller-Hinton (MH) broth or agar, or media containing
Campylobacter growth supplement and Preston Campylobacter selective supplement
(Oxoid) when necessary. MH media were supplemented with various concentrations of
Ery or tylosin when necessary. Strains were grown at 42˚C under microaerophilic
conditions using CampyGen gas pack (Oxoid) in enclosed jars.

Antibiotic susceptibility test
Minimum Inhibitory Concentrations (MICs) were determined using the standard
agar dilution method as recommended by the CLSI (Formerly NCCLS) (CLSI, 2006). C.
jejuni ATCC 33560 was used as a quality control strain and the quality control range of
Ery MIC is 1-4 µg/ml when incubated at 42˚C for 24 hours. Erythromycin stock solutions
of concentration 25 mg/ml in 100% ethanol were stored at -20˚C. To prepare plates for
MIC test, Ery stock solution was vortexed vigorously and diluted to 5.12 mg/ml (highest
concentration) and subsequently diluted two-fold with sterile dd H20 until a final
22

concentration of 0.005 mg/ml was obtained. Two-ml of desired concentration of Ery and
1 ml of defibrinated sheep blood (Cleveland Scientific, Cleveland, OH) were added in 17
ml agar deep for preparing agar dilution plates with 11 concentrations ranging from 512
µg/ml to 0.5 µg/ml. Plates with Ery concentration of 0 µg/ml were made with dd H20 in
place of Ery and were used as positive control. To prepare inoculum, well-isolated C.
jejuni colonies from a fresh agar plate (grown at 42oC for 24 hrs) were suspended in MH
broth to a turbidity equivalent to that of a 0.5 McFarland standard using VITEK
Colorimeter (bioMerieux, Inc., Durham, NC). Agar dilution test was performed using
Cathra Replicator System (Oxoid). The growth and end points were monitored following
24 hr of microaerophilic incubation at 42oC. According to the new breakpoints
recommended by CLSI (CLSI, 2006), Ery MIC ≤8 μg/ml and ≥ 32 μg/ml are considered
susceptible and resistant, respectively. Ery was purchased from Sigma chemical Co., St.
Louis, MO.

In vitro selection of macrolide-resistant mutants
Erythromycin (SIGMA) or tylosin tartrate (MP Biomedicals) was used as
selective agent for selecting spontaneous macrolide-resistant mutants in vitro. Briefly,
100 μl of wild-type Ery-sensitive NCTC 11168 cultures were plated on MH plates and
grown overnight at 42˚C under microaerophilic conditions. The fresh cells were then
harvested from plates using sterile MH broth. Cell suspension were then plated on
increasing concentrations of erythromycin and tylosin (4- to 16-fold the initial MIC of
NCTC 11168). Following 3-5 days incubation under microaerophilic conditions at 42˚C,
single macrolide resistant colony on selective plates were selected, cultured in MH broth
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and stored at -80 ˚C. The Ery-resistant and tylosin-resistant mutants obtained from the
first round of selection were grown in MH broth containing sublethal concentrations of
Ery and tylosin, respectively, and then plated on selective plates again for selecting
mutants with higher level of resistance. If needed, the procedure was repeated to obtain
high level macrolide resistant mutants. All in vitro-selected mutants were subjected to
MIC test using standard agar dilution method as described above. In addition, genomic
DNA was prepared from each mutant and used for PCR amplification and sequence
analysis of 23S rDNA and ribosomal proteins L4 and L22 genes as detailed below.

Polymerase Chain Reaction (PCR)
PCR was performed to analyze the sequences of domain V of the 23S rRNA
genes, ribosomal proteins L4 and L22 genes, and major outer membrane protein gene
cmp in C. jejuni. All primers used for PCR are described in Table 2. PCR was performed
with a total volume of 50µl containing 1µl of 10 mM concentration of each of the
deoxynecleoside triphosphates, 5µl of Mg2+-free thermophilic DNA polymerase 10X
buffer, 5µl of 25mM MgCl2, 2µl of forward primer (5 pmol/µl), 2µl of reverse primer (5
pmol/µl), 2.5µl of DNA template, 32µl of dd H20, and 0.5µl of Taq DNA polymerase
(2.5 U). Cycle for all reactions was 95˚C for 5 minutes followed by 33 cycles of: 95˚C
for 30 seconds for denaturation, 50˚C for 30 seconds for annealing, followed by 72˚C for
1 minute for extension. In all PCR reactions, boiling samples were used as DNA
templates. Briefly, cultures were grown in MH broth at 42˚C for 48 hours under
microaerophilic conditions. One ml of C. jejuni cells were centrifuged for 3 min at
10,000 x g and pellet was suspended in 100µl sterile ddH20. The tube containing cell
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suspensions was placed in boiling water for 10 minutes, followed by centrifugation for 3
minutes at 10,000 x g. Seventy µl of the supernatant was carefully transferred to a clean
tube and used as a DNA template for PCR. The PCR products were run together with 1
kb DNA ladder (Promega) in 1% agarose gel at 100 constant volts for 30 minutes. The
gel was stained by ethidium bromide and digital photographs of gels were taken using
FluoChem 5500 digital imaging system (Alpha Innotech).

Sequence Analysis
PCR products were purified using QIAquick PCR Purification Kit (Qiagen).
Purified products were sequenced using ABI 3730 DNA Sequencer at UTK Molecular
Core Facility. Sequences were aligned suing NCBI BLAST software at NCBI website
(http://www.ncbi.nih.gov/blast/bl2seq/wblast2.cgi) and mutations identified.

Insertional mutagenesis of cmeB gene
Isogenic cmeB mutants of various Campylobacter jejuni isolates were constructed
using natural transformation. Wild-type strain NCTC 11168 or its Ery-resistant
derivatives selected in vitro or in vivo was spread on MH agar plates, followed by
incubation at 42° C for 48 hours. Cells were harvested with MH broth and adjusted to the
approximate concentration of 3 x 109 CFU/ml. 500μl of C. jejuni cell culture was added
to 15ml tubes containing 1ml MH agar. The tubes were incubated 3 hours. Following
uncubation, 5μl of C. jejuni 9B6 genomic DNA was mixed with 500μl of C. jejuni cells
by pipetting. Tubes were again incubated for 3 hours. To select transformants, cultures
were spread on MH plates containing kanamycin 30μg/ml and incubated 48 hours. All
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incubation was performed under microaerophilic conditions at 42° C.

Exposure of low-level Ery resistant Campylobacter mutants to subtherapeutic dose
of tylosin in chickens
Two independent experiments were conducted in chickens using tylosin at the
dose used for growth promotion. In each experiment, day-old broiler chicks (gift from
commercial company Hubbard Hatchery, Pikeville, TN) were randomly assigned to two
groups (9-10 per group). All birds were placed in sanitized wire cages with unlimited
access to feed and water. In the first experiment, chickens in the control group received
nonmedicated feed. Chickens in the treatment group received the complete feed
supplemented with tylosin (Elanco Animal Health). All feed was prepared by the feed
mill at Johnson Animal Research and Teaching Unit. Medicated feed was prepared in
accordance with the label for preparation of medicated feed used for growth promotion of
chickens to obtain a final concentration of 50 mg/kg. To confirm that the birds were
Campylobacter-free, on day 12 (prior to inoculation with C. jejuni), sterile swabs were
used to take cloacal swab samples from each bird. Swabs were immediately placed in
small sterile tubes containing 1 ml MH broth. Tubes were briefly vortexed and 100 µl of
each sample spread on MH plates containing growth and selective supplements, and
plates were incubated at 42˚C under microaerophilic conditions for 48 hours. All birds
were Campylobacter-free prior to inoculation. At 15 days of age, all birds were
inoculated with approximately 107 CFU of fresh C. jejuni DC2 (Ery MIC= 32µg/ml;
Table 1) culture via oral gavage. Cloacal swabs were then collected on 17, 22, 29, 36, 43,
and 50 days of age. Samples from each bird were were diluted serially, and each dilution
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was spread onto two different types of MH plates: one containing Campylobacterspecific growth and selective supplements (SR084E and SR117E; Oxoid) to recover the
total Campylobacter populations, and the other containing 8 µg/ml Ery (for control group)
or 128µg/ml Ery (for treatment group) in addition to the same growth and selective
supplements to recover the Campylobacter populations that were considered not
susceptible to Ery. Campylobacter colonies were counted following 48 h of incubation at
42oC under microaerophilic conditions. Individual colonies were also collected from
selective plates for each chicken and was used for MIC testing. Representative isolates
were also selected for PCR amplification and sequence analysis of 23S rDNA and rplD
and rplV genes encoding ribosomal proteins L4 and L22. Poultry is usually
Campylobacter-free for the first 2-3 weeks of age in commercial conditions. Therefore,
inoculating birds with C. jejuni at day 15 in this study mimics commercial broiler
production conditions.
In the second experiment, chickens were randomly assigned to two groups and
chickens in both group received the feed supplemented with tylosin with a final
concentration of 50 mg/kg feed. At 15 days of age, each chicken within each group was
either inoculated with approximately 107 CFU of fresh C. jejuni DC2 (Ery MIC= 32µg/ml)
or DC26 (Ery MIC= 64µg/ml; obtained from the first chicken experiment) via oral
gavage. Cloacal swabs were collected on 20, 34, and 48 days of age. Representative
isolates from each bird on each sample day were subjected to differential plating, MIC
testing, and PCR sequencing analysis as described above.
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In vitro stability of Ery resistance
One low-level Ery resistant mutant (DC2; Ery MIC= 32µg/ml) and two high-level
Ery resistant mutants (DC3 and DC6; Ery MICs> 512µg/ml) (Table 1) were used for in
vitro stability test and all these mutants are chicken isolates derived from the same parent
strain NCTC 11168 (Lin et al, 2007). Experimental design is outlined in Figure 1. To
perform in vitro stability test, all mutants were inoculated in antibiotic-free MH broth and
grown in microaerophilic conditions at 42˚C. Every 48-72 hours, 10 µl of each culture
was subcultured in 4 ml fresh MH broth (1:400 dilution) for a total of 33 passages.
Following passages 10, 20, and 33, the cultures were serially diluted (10-fold dilution) in
MH broth and plated on both MH agar plates and MH agar plates supplemented with Ery
at final concentration of 8 µg/ml (DC2) or 128 µg/ml (DC3, DC6). Plates were incubated
at 42˚C under microaerophilic conditions for 48 hours. Total numbers of colonies on each
type of plate were counted and compared. In addition, following passage 33 differential
plating, 10 colonies for each mutant were randomly chosen from MH agar plates and
were subjected to Ery MIC test using standard agar dilution method as described above.

In vivo stability of Ery resistance using chicken model system
Day-old broiler chicks (gift from commercial company Hubbard Hatchery,
Pikeville, TN) were randomly assigned to two groups (12-13 birds per group). All birds
were placed in sanitized wire cages with unlimited access to feed and water. Feed was
nonmedicated feed without any antibiotic additives and was prepared by the feed mill at
Johnson Animal Research and Teaching Unit. At 3 days of age, all birds were inoculated
with approximately 107 CFU fresh C. jejuni culture via oral gavage. Chickens in group A
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were inoculated with C. jejuni DC2, a low-level Ery resistant C. jejuni mutant (MIC=
32µg/ml) that was obtained from previous chicken study (Lin et al 2007). In group B, all
chickens were inoculated with a highly EryR mutant DC6 (MIC> 512µg/ml) that was also
obtained from previous chicken study (Lin et al 2007). Cloacal swabs were then collected
on day 12, 22, 38, and 47. Isolation of Campylobacter and differential plating for
enumerating the proportion of the mutant colonies were conducted as described above.
Samples from group A were subjected to differential plating on MH plates supplemented
with growth and selective supplements, and with or without Ery 8µg/ml. Samples from
group B were subjected to differential plating on MH plates supplemented with growth
and selective supplements, and with or without Ery 128µg/ml. Representative isolates
from each chicken were selected for Ery MIC test. Selected isolates were also subjected
to PCR amplification and sequence analysis of 23S rDNA and rplD and rplV genes
encoding ribosomal proteins L4 and L22. To confirm that C. jejuni strain used for
inoculation was the same strain collected from cloacal swabs, major outer membrane
protein gene cmp (MOMP), a good target for molecular typing in Campylobacter (Huang
et al. 2005), was PCR amplified in the input strain and a representative output isolates
and subjected to sequencing analysis. MOMP gene sequencing revealed no difference
between input strain and output isolates.

Detection limit and statistical analysis
In all chicken experiments, the detection limit of the plating methods is
approximately 100 CFU/g of feces. Student’s t test was used to examine the significance
of differences in Campylobacter colonization levels (log transformed CFU/g feces) at
29

each sampling point between two treatment groups. A P value of <0.01 was considered
significant.
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4. RESULTS
Colonization of EryR mutants in response to tylosin treatment.
In the first chicken experiment in which C. jejuni DC2 was used to inoculate
chickens either receiving medicated or nonmedicated feed, all chickens, including the
ones with the medicated feed, were successfully colonized by C. jejuni DC2 on d 17
(two days after inoculation) (Figure 2). The shedding level of Campylobacter in feces
was consistently higher (up to 1.8 log10 units) in the chickens given nonmedicated feed
than in those given tylosin-containing feed, except that on d 50 the shedding levels of C.
jejuni for the nonmedicated group was slightly lower (but the difference was not
statistically significant: P > 0.05) than those from medicated group (Figure 2).
In the second chicken experiment, chickens were assigned to two groups that
were inoculated with either low-level EryR C. jejuni DC2 (Ery MIC= 32µg/ml) or DC26
(Ery MIC= 64µg/ml) but all chickens were treated with medicated feed throughout the
study. All chickens were successfully colonized by DC2 or DC26 at 20 days of age (5
days after inoculation) (Figure 3). Both groups of chickens displayed similar shedding
levels of Campylobacter throughout the study although DC2 seemed colonize slightly
better than DC 26 on day 20 (Figure 3).
Representative C. jejuni isolates derived from chickens were analyzed by PCR
(for the MOMP gene) (Figure 4) and subsequent sequence analysis, which revealed that
the MOMP gene sequences of the mutants (output) were identical to strain used as
inoculum (input).
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Effect of prolonged low dose tylosin treatment on the emergence of high-level EryR
C. jejuni in chickens
In the first experiment, day-old broiler chicks were placed in two groups,
receiving feed supplemented with tylosin at a concentration of 50mg/kg (treatment
group), or nonmedicated feed (control group). After inoculation of chickens with DC2 at
15 days of age, cloacal swabs collected every 2-7 days and used to determine the
percentage EryR populations of C. jejuni, and levels of Ery resistance for both groups. In
control group, all isolates obtained from chickens at 29 days of age became susceptible to
Ery as determined by MIC test (Figure 5, Table 3), which was also confirmed by
differential plating method. Each chicken in the treatment group consistently shed EryR C.
jejuni throughout the study (Figure 5, Table 3). By day 29, and every sample day
thereafter, mutants with Ery MIC of 64 µg/ml were isolated in the treatment group (Table
3). However, no high-level EryR organisms were selected throughout the study. These
results suggest that low-level Ery resistance in C. jejuni is not stable in the absence of
antibiotic selection pressure and long-term exposure of C. jejuni to low-dose tylosin may
not be enough for developing high-level Ery resistance in C. jejuni.
To further confirm the finding from above chicken experiment, DC2 together with
its new derivative DC 26 (Ery MIC = 64 µg/ml; from above chicken study) were used to
challenge chickens receiving tylosin-containing feed (50 mg/ml). As shown in Table 4,
regardless of the mutants used for inoculation, none of chickens shed high-level EryR C.
jejuni (MIC > 512 µg/ml) with up to 33 days continuous tylosin treatment, which is also
consistent with differential plating result. However, in the group inoculated with C. jejuni
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DC2, a mutant with Ery MIC of 256µg/ml was obtained on day 48 (Table 4) while in the
group inoculated with DC26 mutants with MIC of 128µg/ml were selected on each
sampling day (Table 4). Together, these findings confirmed the results from the first
chicken experiment and indicated that long-term antibiotic selection pressure should
work together with other factors to select high-level Ery resistance in Campylobacter.

In vitro stability of Ery resistance in C. jejuni
C. jejuni strains DC2 (Ery MIC= 32µg/ml) and two high-level EryR mutants DC3
and DC6 (Ery MIC> 512µg/ml) were used for in vitro stability test. All these three EryR
mutants are chicken isolates derived from NCTC 11168 in a previous chicken experiment
(Lin et al. 2007). As shown in Figure 6, more than 60% of DC2 populations could still be
selected on MH plates containing 8 µg/ml Ery after 10 passages while all DC3 as well as
DC6 populations grew well on MH plates containing 128 µg/ml of Ery. By passage
number 20 and 33, Ery-resistant populations in DC2 culture were dramatically dropped to
13% and 7%, respectively (Figure 6). However, both DC3 and DC6 displayed high
stability after 20 and 33 passage; near100% populations could still be recovered on MH
plates containing 128 µg/ml of Ery (Figure 6). The differential plating results (Figure 6)
were also confirmed by Ery MIC tests of representative isolates selected on MH plates
for passage 33. Majority of DC2 isolates showed Ery MIC of 2µg/ml that is comparable
with the MIC of wild-type sensitive level. However, all tested DC3 and DC6 had Ery
MIC> 512µg/ml. Together, these results indicated that high-level Ery resistance (Ery
MIC > 512µg/ml) in C. jejuni is stable in vitro while low-level Ery resistance is not.
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In vivo stability of Ery resistance in C. jejuni
Both DC2 and DC6 strains were chosen for in vivo stability test of Ery resistance
in C. jejuni using chicken model system. At 12 days of age (9 days after C. jejuni
inoculation), each chicken in both groups was colonized by DC2 or DC6 with average
colonization level from 3.7 to 4.9 Log10 units (Figure 7). Differential plating showed no
EryR C. jejuni mutant was detected in DC2-inoculated chickens by day 38 using MH
selective plates containing 8 µg/ml Ery (Figure 8). However, high-level Ery resistance
was maintained throughout the study; approximate 100% of C. jejuni populations from
chicken inoculated with DC6 grew on MH selective plates containing 128 µg/ml of Ery
for the entire study, suggesting high-level Ery resistance is very stable in vivo (Figure 8).
MIC test of all randomly selected isolates from each individual chickens further
confirmed these findings (Table 5). For low-level EryR mutant DC2, the instability of
low-level Ery resistance was also observed in chickens as early as 9 days after
inoculation (day 12); two of 12 isolates from 12-day-old chicken displayed reduced Ery
MIC (16 µg/ml) (Table 5). With further growth of DC2 in chickens without tylosin
selection pressure, majority of isolates from chickens inoculated with DC2 displayed Ery
MIC similar to that of wild-type sensitive strain on day 38 and 47f (Table 5). In contrast,
all isolates from chicken inoculated with DC6 consistently displayed high-level Ery
resistance (MIC> 512µg/ml), regardless sampling date (Table 5).

Molecular mechanisms of Ery resistance in mutants selected in vitro and in vivo
Thirty in vitro-selected and thirty three in vivo-selected EryR C. jejuni mutants (all
NCTC 11168 derivatives) were subjected to PCR amplification of 23S rRNA gene and
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rplD and rplV genes encoding ribosomal proteins L4 and L22, respectively (Figure 9).
The sequences of these PCR products were aligned to corresponding sequence of parent
strain NCTC 11168 to identify specific mutations occurred in ribosome.
With respect to 23S rRNA gene, all high-level EryR isolates selected in vitro
(JL287-289) displayed an A→C point mutation at position 2074 (Table 6) while all highlevel EryR isolates selected in vivo (DC3, 6, 9, 31, 32, 33) displayed a different point
mutation at the same position (A2074G ) (Table 7). According to sequence results, it
appeared that A2074C mutation was present in two of the three copies of the 23S rRNA
gene in mutants selected in vitro, because the sequence chromatogram showed double
peaks in the same position where the C peak was two times higher than the A peak
(Figure 10). Regardless of selection environment, none of EryR mutants with Ery MIC ≤
512µg/ml displayed point mutation in the domain V of the 23S rRNA genes (Table 6 and
7).
Changes in ribosomal protein L4 were not detected in mutants selected in vitro
(Table 6) and were only observed in majority of low-level EryR isolates selected in vivo
(22 of 25 isolates, MIC range 8- 64µg/ml) (Table 7). Specifically, these mutants showed
a G→D change either at positions 74 or 57 (Table 7, Figure 12). The G74D modification
in ribosomal protein was stable in the presence of continuous tylosin selection pressure
(DC21-27 in Table 7). However, in the absence of tylosin selection pressure in feed, the
Ery MIC of randomly selected isolates decreased (DC28-30), consistent with the loss of
specific G74D point mutation in L4 protein (Table 7).
Modification in ribosomal protein L22 was only observed in EryR mutants
selected in vitro but not in the mutants selected in vivo (Table 7). Specifically, a 335

amino acid insertion (TSH) at position 98 in protein L22 was observed in isolates
selected in vitro with wide Ery MIC range from 32 to 512 µg/ml (Table 6, Figure 11). It
seemed that use of specific selective agent (Ery or tylosin) did not affect development of
Ins98TSH modification in L22 protein (Table 6).
The different mutations in EryR mutants were summarized in Table 8.
Interestingly, some of EryR mutants, either selected in vivo or selected in vitro, did not
display any mutations in the sequenced three gene targets (Table 6-8). Such mutants
include four in vivo-selected mutants (DC1, DC4, DC11, and DC29) with Ery MIC
ranging from 4 to 64 µg/ml (Table 7 and 8) and 50% in vitro-selected mutants with Ery
MIC ranging from 8-128 µg/ml (Table 6 and 8).

Contribution of CmeABC efflux pump to the acquired Ery resistance
To determine the contribution of the CmeABC efflux pump to the acquired Ery
resistance, CmeABC mutation was transferred to selected EryR mutants and Ery MIC of
each isogenic CmeB mutant was measured by standard agar dilution method. As shown
in Table 9, regardless the presence of specific mutation in 23S rRNA gene (DC32, JL287,
JL288), in L4 protein (DC22, DC27), in L22 protein (Jl290, JL301, JL303), or absence of
any mutation (JL283, JL284), inactivation of cmeB dramatically reduced Ery MIC (8 –
1024 folds) when compared to its parent strain (Table 9), indicating that CmeABC works
synergistically with other mechanisms to maintain high-level and low-level Ery
resistance in C. jejuni selected in vivo and in vitro.
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5. DISCUSSION

The results of this study reveal several unique features with respect to macrolide
resistance development, stability, and associated molecular mechanisms in
Campylobacter jejuni. First, exposure time to subtherapeutic level of tylosin is not a sole
factor contributing to emergence of highly EryR Campylobacter. Prolonged exposure of
low-level EryR C. jejuni (MIC = 32 or 64 µg/ml) to growth promoter tylosin did not
select for high-level EryR C. jejuni (Table 3, 4). Second, high-level Ery resistance (MIC
>512 μg/ml) displayed remarkably stability in vitro and in vivo. (Figures 6, 8, Table 5).
However, the low-level Ery resistance (MIC = 32 μg/ml) was not stable in vitro and
majority of C. jejuni were sensitive to Ery after 20 passages (Figure 6). The instability of
low-level Ery resistance was also observed in chickens as early as 9 days post inoculation
and EryR mutants were rarely isolated 35 days post inoculation (Table 5, Figure 8). Third,
sequencing analysis of 23S rDNA, L4 and L22 genes revealed that molecular
mechanisms contributing to Ery resistance in C. jejuni differ between high-level and lowlevel resistant isolates and between isolates selected in vivo and in vitro. (Figures
10,11,12, Tables 6,7,8, 9). Fourth, mutation in CmeABC efflux pump drastically reduced
MIC of Ery for EryR mutants selected in vitro and in vivo, indicating CmeABC worked
synergistically with other mechanisms to confer Ery resistance in C. jejuni (Table 9).
Together, these findings indicated that C. jejuni utilize complex and different
mechanisms to develop Ery resistance in vitro and in vivo
Recently, Lin et al., (2007) conducted a study to examine the development of Ery
resistance in C. jejuni in chickens upon exposure to growth promoter tylosin. When
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tylosin was given to the chickens in feed at a growth-promoting dose, EryR mutants
emerged in the birds after prolonged exposure to the antibiotic. In experiment 1, when
chickens were inoculated with Ery sensitive C. jejuni strain at 3 days of age, EryR
mutants were finally detected in the chickens on 31 days after inoculation (DAI 31) and
DAI 38 but not in chickens at DAI 17, and 24; majority of EryR mutants from DAI 31
and 38 displayed high-level Ery resistance (MIC > 512 µg/ml). In experiment 2, the
chickens inoculated with the same sensitive C. jejuni strain at 17 days of age started to
shed EryR mutants at DAI 17; but all EryR mutants only showed low-level Ery resistance
with MIC ranging from 8 to 16 µg/ml. Further 1-week exposure did not promote
emergence of any mutants with higher level Ery resistance at DAI 24. Although these
findings indicate that long-term use of tylosin as a growth promoter selects for EryR
Campylobacter in chickens, it is intriguing why highly Ery-resistant Campylobacter
emerged without pre-emergence of low-level EryR mutants at DAI 24 in experiment 1. Is
the length of exposure time a major factor contributing to emergence of high-level EryR C.
jejuni? Does emergence of highly EryR Campylobacter mutants require stepwise
accumulation of various identified mutations in ribosome? To address these issues, in this
study, we first conducted two chicken experiments to determine if long-term exposure of
two low-level EryR Campylobacter mutants results in emergence of high-level Ery
resistant mutants. The findings from this study (Table 3 and 4) strongly suggest that
exposure time is not a sole factor selecting for high-level Ery resistant C. jejuni. Some
unknown factors in conjunction with continuous antibiotic selection pressure may
determine the rate of occurrence of highly EryR Campylobacter. For example, gut
microflora may play an important role. Campylobacter species have an exceptional
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ability for taking up heterologous DNA. Thus, interspecies exchange of genetic material
between Campylobacter and other bacterial flora (e.g. macrolide resistant populations) in
intestine may lead to the emergence of Ery resistant Campylobacter. Other factors, such
as anatomy, physiology, and specific tissue concentration of tylosin, may also affect the
rate of emergence of high-level EryR Campylobacter.
Sequence analysis revealed that all high-level EryR mutants (MIC >512 μg/ml)
selected in vivo displayed the specific A2074G mutation in 23S rRNA gene while
specific mutations in L4 (G74D or G57D) were widely found in low level EryR mutants
(Ery MIC = 8-64 μg/ml) selected in vivo (Table 7). No single EryR mutant displayed
mutations in both 23S rRNA gene and L4 protein, which suggest that specific mutations
in L4 contribute to low-level Ery resistant but are not essential for further development of
high-level resistance in C. jejuni in chicken. Similarly, no single in vitro-selected EryR
mutant displayed mutations in both 23S rRNA gene and L22 protein either (Table 6).
This finding is also consistent with recent in vitro study (Cagliero et al. 2006b) and also
suggests that 23S rRNA gene mutation and change in L4 protein or L22 protein may not
co-exist in EryR Campylobacter. However, it does not mean that low-level Ery resistance
is not required for developing high-level Ery resistance. We have obtained some EryR
mutants that do not have any mutations in domain V of the 23S rDNA, L4 or L22 genes,
such as DC1, DC4, and DC11 selected in vivo, and JL283-289 selected in vitro (Tables
6,7,8), The Ery resistance mechanisms in these mutants needs to be determined in the
future and the novel mechanisms required for low-level resistance in these mutants may
make C. jejuni survive better under selection pressure and facilitate the development of
high-level Ery resistance in Campylobacter.
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Campylobacter jejuni has displayed unique feature with respect to the fitness and
stability of antibiotic resistance (Luo et al. 2005; Zhang et al. 2003). Chromosomal
mutation- or plasmid acquisition-mediated antibiotic resistance generally incur a fitness
cost in bacteria (Andersson & Levin 1999; Levin et al. 2000). However, Luo et al (2005)
demonstrated that FQ resistance in Campylobacter is very stable and FQ-resistant
mutants do not show a fitness cost in vivo. Interestingly, FQ resistant Campylobacter
mutants are ecologically more competitive in the colonization of chickens than their FQsensitive parent strain even in the absence of antibiotic selection pressure (Luo et al.
2005). Does Ery resistance in Campylobacter have the same distinct feature? It has been
observed that high-level Ery resistance that is associated with A2075G and A2074C
mutations in 23S rRNA in Campylobacter was stable in vitro in the absence of macrolide
selection pressure (Gibreel et al. 2005; Kim et al. 2006). In this study, both in vitro and in
vivo experiments provided compelling evidence that low-level Ery resistance is not stable
in C. jejuni while high-level Ery-resistant mutants displayed remarkably stability. The
phenotype of Ery resistance stability in C. jejuni could be contributed by two factors:
reverse mutation rate of specific Ery resistance associated mutation (e.g. A2074G in 23S
rRNA gene) and fitness cost of EryR Campylobacter mutant due to acquisition of specific
mutation(s). It is technically difficult to assess reverse mutation rate of specific Ery
resistance associated mutation. However, given the fact that the emergence of
spontaneous EryR mutants in vitro is at a low frequency in Campylobacter (Lin et al.
2007), it is likely that in vitro reverse mutation rate is also low. With respect to point
mutation in 23S rRNA that is associated with high-level Ery resistance, acquisition of
such mutation either alone or with unknown compensatory mutation(s) may result in little
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fitness cost. Consequently, the highly EryR C. jejuni mutants may not be outcompeted by
sensitive strain after successive multiplication either in vitro or in vivo with removal of
antibiotic selection pressure, leading to high stability or persistence phenotype as we
observed in this study. In contrast, changes in L4 or L22 may result in increased fitness
cost in low-level EryR C. jejuni mutants according to our findings in this study. Thus, as
soon as sensitive C. jejuni emerges in total populations due to the loss of specific
characterized mutation (e.g. G74D in L4) or other unknown mutation(s), the sensitive
populations, which display higher fitness than low-level EryR C. jejuni mutants, will
eventually become dominant. The randomly selected isolates (DC28-30) from the 47-day
old chickens that have been inoculated strain DC2 (Ery MIC = 32 ug/ml) and received
non-medicated feed (Table 7) showed reduced MIC (1-8 ug/ml) with or without specific
G74D mutation in L4, strongly suggesting that G74D mutation together with other
uncharacterized mutation(s) contribute to low-level resistance and none of these
mutations is stable in vivo.
Previous investigation on the mechanisms of macrolide resistance in
Campylobacter either focused on the comparison of isolates from various origins or
examined macrolide resistant mutants selected in vitro, greatly limiting the interpretation
of association of specific molecular mechanisms with acquired resistance and limiting
elucidation of macrolide resistance development in vivo (Cagliero et al. 2006b; Corcoran
et al. 2006; Gibreel et al. 2005; Kim et al. 2006; Mamelli et al. 2005). Distinct from these
studies, we examined a panel of in vitro- and in vivo-selected EryR C. jejuni mutants that
are all derived from the same parent strain C. jejuni 11168. Sequence analysis and Ery
MIC test revealed several unique findings with respect to the molecular mechanisms of
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Ery resistance development in Campylobacter. First, with respect to high-level Ery
resistance (MIC > 512 µg/ml), all mutants selected in vivo displayed A2074G mutation
while all mutants selected in vitro displayed A2074C mutation in 23S rDNA. Different
environment (in vitro vs. in vivo) may be a major factor causing such difference.
However, we cannot rule out the possibility that different selective agents may select for
different point mutation. In this study, tylosin was supplemented in feed for selecting
EryR mutants developed in chicken and erythromycin was used in vitro to select highlevel EryR mutants (JL287-289). We have made extensive efforts to select high-level
EryR mutants using tylosin as selective agent in vitro. However, we failed to obtain highlevel EryR mutants with point mutation in 23S rDNA using tylosin for mutant selection in
vitro, further suggesting selection pressure resulting from tylosin alone may not be
enough to promote emergence of high-level EryR C. jejuni mutants. Second, with respect
to low- and intermediate-level Ery resistance development, growth environment seems to
determine specific type of modification in ribosomal protein that confers Ery resistance.
Although one study (Cagliero et al, 2006b) showed one in vitro-selected EryR C. jejuni
mutant acquired G74D mutation in ribosomal protein L4, we only identified such
mutation and another novel mutation G57D in L4 in mutants selected in vivo but not in
vitro. Modification in ribosomal protein L22 (TSH98 insertion) was only found in EryR
mutants selected in vitro with Ery MIC from 32 µg/ml to 512 µg/ml, regardless specific
selective agent used (tylosin or Ery). Finally, some of in vivo-selected mutants (DC1,
DC4, and DC11) and in vitro-selected mutants (JL276-JL279, Jl283-JL286, and JL292JL298) do not have any mutations or modifications in domain V of 23S rRNA gene and
in ribosomal proteins L4 and L22. Some of these mutants have Ery MIC as high as 128
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µg/ml (e.g. JL284-286). Molecular mechanisms of Ery resistance in these isolates need
to be examined in the future. Taken together, these findings indicated that C. jejuni utilize
complex and different mechanisms to develop Ery resistance in vitro and in vivo.
CmeABC efflux pump is widely noted as being linked to macrolide resistance in C.
jejuni (Lin et al., 2007; Cagliero et al., 2006; Gibreel et al., 2005; Mamelli et al., 2005;
Martinez and Lin, 2006). In these studies, inactivation of CmeABC by site-directed
mutagenesis or inhibition of CmeABC by efflux pump inhibitor dramatically reduced Ery
MIC in wild-type sensitive strains or in Ery-resistant mutants, indicating CmeABC
contributes to both intrinsic and acquired Ery resistance. In this study, regardless of the
presence of specific target mutations in the ribosome, inactivation of CmeB greatly
reduced the Ery resistance of all EryR isolates (Table 9), indicating that CmeABC
multidrug efflux pump is a significant player in maintaining the acquired resistance to
Ery. In all low-level resistant isolates from in vivo and in vitro studies, inactivation of
CmeB led to a drastic reduction in Ery MIC to a level that was even below that of the
wild-type strain. This can be explained by the known role of CmeABC in the intrinsic
resistance to various antibiotics (Lin et al. 2002). With respect to three high-level
resistant isolates (MIC>512μg/ml), inactivation of CmeB led to the decrease of Ery MIC
to 64 µg/ml in DC32 and JL288 and to 0.5 µg/ml in JL287. It is still unknown why
inactivation of CmeB in two similar in vitro-selected highly Ery-resistant mutants (JL287
and JL288) led to different MIC reductions. The mechanism of how CmeABC
synergistically functions together with other mechanism(s) to confer Ery resistance in
these mutants needs be examined.
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Table 1. Key Campylobacter jejuni strains used in this study.
Strain

Description

NCTC 11168

wild-type, Erya sensitive

JL11

ATCC 33560, quality control strain for MIC testing

ATCC

9B6

cmeB::kan, C. jejuni 81-176 derivative. Also named
JL30

(Lin et al. 2002)

DC2

Ery resistant (MIC = 32µg/ml), NCTC 11168
derivative isolated from chicken treated with growth
promoter tylosin

(Lin et al. 2007)

DC3

Ery resistant (MIC > 512µg/ml), NCTC 11168
derivative isolated from chicken treated with growth
promoter tylosin

(Lin et al. 2007)

DC6

Ery resistant (MIC > 512µg/ml), NCTC 11168
derivative isolated from chicken treated with growth
promoter tylosin

(Lin et al. 2007)

DC26

Ery resistant (MIC= 64µg/ml), isolated from chicken
inoculated with DC2 and treated with growth
promoter tylosin

this study

a

Ery: erythromycin
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Source
ATCC (cat No.
700819)

Table 2. PCR primers used in this study.
Name

Sequence

Amplicon
size

L4 F

5’- GTA GTT AAA GGT GCA GTA CCA -3’

L4 R

5’- GCG AAG TTT GAA TAA CTA CG -3’

L22 F

5’- GAA TTT GCT CCA ACA CGC -3’

L22 R

5’- ACC ATC TTG ATT CCC AGT TTC -3’

23SribF

5’- GTA AAC GGC GGC CGT AAC TA -3’

23SribR

5’- GAC CGA ACT GTC TCA CGA CG -3’

MOMPF

5’-ATG AAA CTA GTT AAA CTT AGT TTA-3’

MOMPR

5’-GAA TTT GTA AAG AGC TTG AAG -3’

767 bp

(Cagliero
et al.
2006b)

568 bp

(Cagliero
et al.
2006b)

699 bp

(Jensen &
Aarestrup
2001)

1.3 kb
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Source

(Huang et
al. 2005)

Table 3. Erythromycin MICs of C. jejuni isolates from chickens receiving nonmedicated feed (Control) or feed supplemented with tylosin (50 mg/kg) (Treatment).
Chicken group a

Control

Day of age
17
22

Ery MIC (µg/ml)
16
4
16
32
4
1
2
4
1
2
4
1
2
4
16
32
64
16
32
64
32
64
16
32
64
16
32

29
36
43
50
17
22
29

Treatment

36
43
50

a

# of isolates
9
1
6
2
9
4
2
3
6
2
1
4
3
2
3
3
1
9
6
1
8
2
2
6
1
1
9

Each chicken was inoculated with approximately 107 CFU of C. jejuni DC2 (Ery MIC=
32µg/ml) at 15 days of age.
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Table 4. Erythromycin MICs of C. jejuni isolates obtained from chickens receiving feed
supplemented with tylosin (50 mg /kg).
Inoculuma

DC2 (MIC= 32µg/ml)

Day of Age
20

Ery MIC (µg/ml)
32
64
16
32
64
32
256
64
128
64
128
64
128

34
48
20

DC26 (MIC= 64µg/ml)

34
48

a

# of isolates
9
1
2
7
1
9
1
7
3
8
2
5
1

Each chicken was inoculated with approximately 107 CFU of either C. jejuni DC2 (Ery
MIC= 32µg/ml) or DC26 (Ery MIC= 64µg/ml) at 15 days of age.
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Table 5. In vivo stability of Ery-resistance in C. jejuni.
Inoculum

Day of age
12
22

DC2 (Ery MIC= 32µg/ml)

38
47

DC6 (Ery MIC> 512µg/ml)

12
22
38
47
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Ery MIC (µg/ml)
16
32
4
16
32
4
2
1
.5
1
2
4
8
>512
>512
>512
>512

# of isolates
2
10
3
8
1
6
2
4
2
1
2
2
1
13
13
13
13

Table 6. Mutations in 23SrRNA and changes in ribosomal protein L22 in C. jejuni
mutants selected in vitro.
Name

Ery MIC
(µg /ml)

Wild- type
NCTC 11168
JL276
JL277
JL278
JL279
JL283
JL284
JL285
JL286
JL287
JL288
JL289
JL290
JL291
JL292
JL293
JL294
JL295
JL296
JL297
JL298
JL299
JL300
JL301
JL302
JL303
JL304
JL305
JL306
JL307
JL308

1
16
8
8
8
64
128
128
128
>512
>512
>512
32
32
8
8
8
8
8
8
8
64
128
512
512
256
256
256
64
256
64

Selective
agent

Ery
Ery
Ery
Ery
Ery
Ery
Ery
Ery
Ery
Ery
Ery
Ery
Ery
Ery
Ery
Ery
tylosin
tylosin
tylosin
tylosin
Ery
Ery
tylosin
tylosin
tylosin
tylosin
Ery
Ery
Ery
Ery

Mutation
in 23S
rRNA
-

Change in
protein
L22
-

Change in
protein L4

Source

-

ATCC
700819

A2074Ca
A2074Ca
A2074Ca
-

Ins 98TSH
Ins 98TSH
Ins 98TSH
Ins 98TSH
Ins 98TSH
Ins 98TSH
Ins 98TSH
Ins 98TSH
Ins 98TSH
Ins 98TSH
Ins 98TSH
Ins 98TSH

-

this
study

- no observed mutation
a
A2074C mutation was present in two of the three copies of the 23S rRNA gene.
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Table 7. Mutations in 23SrRNA, changes in ribosomal protein L4 of in vivo-selected
mutants.
Name

Ery MIC
(µg /ml)

Wild-type
NCTC 11168
DC1
DC2
DC3
DC4
DC5
DC6
DC7
DC8
DC9
DC10
DC11
DC12
DC13
DC14
DC15
DC16
DC17
DC18
DC19
DC20
DC21
DC22
DC23
DC24
DC25
DC26
DC27
DC28
DC29
DC30

1
8
32
>512
8
8
>512
8
32
>512
16
64
64
32
32
32
32
8
16
16
16
32
32
64
32
64
64
64
8
4
1

Selective
Agent

tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin
tylosin

Mutation in
23S rRNA

Change in
protein L4

-

-

Change in
protein
L22
-

A2074G
A2074G
A2074G
-

G74D
G74D
G74D
G74D
G57D
G74D
G74D
G57D
G74D
G74D
G57D
G74D
G57D
G74D
G74D
G74D
G74D
G74D
G74D
G74D
G74D
G74D
-

-
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Source
ATCC
700819

(Lin et
al. 2007)

this
studya

this
studyb

Table 7. Continued.
Name

Ery MIC
(µg /ml)

Selective
Agent

Mutation in
23S rRNA

Change in
protein L4

DC31
DC32
DC33

>512
>512
>512

tylosin
tylosin
tylosin

A2074G
A2074G
A2074G

-

Change in
protein
L22
-

Source

this
studyc

- no observed mutation
a
from individual chicken receiving medicated feed and inoculated with DC2 in the first
chicken experiment to determine development of high-level Ery resistance (pages 27- 28)
b
from individual chicken in experiment to determine in vivo stability (page 35)
c
from individual chicken inoculated with DC6 in chicken experiment to determine in
vivo stability of Ery resistance (page 35).
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Table 8. Summary of ribosome modifications in Ery-resistant C. jejuni mutants selected
in vivo and in vitro.
Strain

# of Ery MIC (µg/ml) Mutations in
isolates
23S rRNA
Wild type
1
1
6
>512
A2074G
in vivoselected mutants 18
8-64
4
8,16,16,32
4
4,8,8,64
3
>512
A2074C
in vitroselected mutants 12
32-512
15
8-128
-, no mutation observed
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Change in Change in
protein L4 protein L22
G74D
G57D
Ins98TSH
-

Table 9. Effect of inactivation of CmeABC multidrug efflux pump on the susceptibility
of EryR C. jejuni mutants to erythromycin.

Strain

Ery
Mutation in Change in
Change in
MIC(µg/ml) 23S rRNA protein L4 protein L22
Wild
1
type
in vivo- selected mutants
DC22
32
G74D
DC27
64
G74D
DC32
>512
A2074G
in vitro- selected mutants
JL283
64
JL284
128
JL287
>512
A2074C
JL288
>512
A2074C
JL290
32
Ins98TSH
JL301
512
Ins98TSH
JL303
256
Ins98TSH
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Ery MIC of CmeABC
mutant (µg/ml)
0.25

0.25
0.25
64
0.25
0.5
0.5
64
0.5
0.5
0.5

in vivo test
Oral inoculation: 107 CFU/ chick, 12-13 chicks per group

Day of Age 3

10

22

38

swab

swab

swab

47

swab

*1 swab per chick, MIC and differential plating for each swab

in vitro test
Inoculation in MH broth, followed by repeated sub-culturing, 1:400 dilution

Passage #

0

10

20

sample

sample

33

sample

*Differential plating for both mutants on each sample day

Figure 1. Experimental design of in-vivo and in-vitro stability test of Ery resistance.
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8

Control
Treatment

a

7
a

Log10 CFU/ g feces

6
b

5
b

4
3
2
1
0
17

22

29

36

43

50

Day of Age

Figure 2. The shedding level of Campylobacter jejuni DC2 in chickens receiving nonmedicated feed and feed supplemented with growth promoter tylosin (50 mg/kg).
Each chicken was inoculated with approximately 107 CFU of C. jejuni DC2 (Ery MIC=
32µg/ml) via oral gavage at 15 days of age. Control chickens received non-medicated
feed. Treatment chickens received feed supplemented with tylosin (50 mg/kg). Each bar
represents the mean log10 CFU/g feces +/- standard deviation in each group. Different
letters above bars on each sampling day denotes significant difference (P < 0.01).
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7

DC2 (MIC=32µg/ml)
DC26 (MIC=64µg/ml)

Log10 CFU/g feces

6
5
4
3
2
1
0
20

34
Day of Age

48

Figure 3. The shedding level of Campyobacter jejuni DC2 or DC26 in chickens
receiving feed supplemented with growth promoter tylosin (50 mg/kg). Each chicken was
inoculated with approximately 107 CFU of C. jejuni DC2 (Ery MIC= 32µg/ml) or DC26
(Ery MIC= 64µg/ml) via oral gavage at 15 days of age. All chickens received feed
supplemented with tylosin (50 mg/kg). Each bar represents the mean log10 CFU/g feces
+/- standard deviation in each group.
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1

2

3

4

5

10 kb

1.5 kb
1 kb

1.3 kb

.25 kb

Figure 4. PCR amplification of Campylobacter MOMP gene for sequence analysis. Lane
1 is 1kb DNA ladder. C. jejuni MOMP gene specific primers were used to amplify
MOMP gene from inoculated strain, DC26 (Lane 2), and from three randomly selected
isolates from chicken feces (Lanes 3-5).
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Control
Treatment
% Ery- resistant mutants

100
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17
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29

36

43

50

Day of Age

Figure 5. Development of Ery resistance in C. jejuni DC2 in response to prolonged low
dose tylosin treatment. Each chicken was inoculated with approximately 107 CFU of C.
jejuni DC2 (Ery MIC= 32µg/ml) via oral gavage at 15 days of age. Control chickens
received non-medicated feed. Treatment chickens received feed supplemented with
tylosin (50 mg/kg). Calculation of % Ery resistant mutants is based on MIC testing using
breakpoint 8µg/ml.
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140

DC2 (MIC=32µg/ml)
DC3 (MIC>512µg/ml)
DC6 (MIC>512µg/ml)

% Ery- resistant population

120
100
80
60
40
20
0
10

20

33

Passage number

Figure 6. In vitro stability of low-level EryR C. jejuni DC2 (MIC= 32µg/ml) and highlevel EryR C. jejuni DC3 and DC6 (MIC> 512µg/ml). Percentage of EryR population was
calculated based on differential plating as described in Materials and Methods.
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7

DC2 (MIC=32µg/ml)
DC6 (MIC>512µg/ml)

b
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Log10 CFU/g feces

a
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Day of Age

Figure 7. The shedding level of low-level Ery-resistant C. jejuni DC2 or high-level Ery
resistant C. jejuni DC26 in chickens receiving non-medicated feed. Each chicken was
inoculated with approximately 107 CFU of either C. jejuni DC2 (Ery MIC= 32µg/ml) or
DC6 (MIC> 512µg/ml) at 3 days of age. All chickens received non-medicated feed. Each
bar represents the mean log10 CFU/g feces +/- standard deviation in each group. Different
letters above bars on each sampling day denotes significant difference (P < 0.01).
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Figure 8. In vivo stability of low-level EryR C. jejuni DC2 and high level EryR C. jejuni
DC6. Each chicken was inoculated with approximately 107 CFU of C. jejuni DC2 (MIC=
32µg/ml) or DC6 (MIC> 512µg/ml) via oral gavage at 3 days of age. Chickens received
non-medicated feed. Calculation of % Ery resistant mutants is based on MIC testing
using breakpoint 8µg/ml.
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(A)

699 bp

(B)

767 bp

(C)

568 bp

Figure 9. PCR amplification of genes associated with erythromycin resistance in C.
jejuni: (A) Amplification of 23S rRNA gene using 23S gene specific primers; (B)
Amplification of full-length ribosomal protein L4 gene (rplD) using rplD specific
primers; and (C) Amplification of full-length ribosomal protein L22 gene (rplV) using
rplV specific primers.
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2074

Wild-type strain

in vivo-selected mutants
A2074G

in vitro-selected mutants

A2074C

Figure 10. Sequence chromatogram of mutations in 23S rDNA of highly EryR mutants
selected in vitro and in vivo.
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Wild type

in vitro-selected mutants

Figure 11. Sequence chromatogram of mutations in ribosomal protein gene L22 in EryR
mutants selected in vitro.
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G221A
Mutation 1

Wild type

Mutation 2

G170A
Figure 12. Sequence chromatogram of mutations in ribosomal protein gene L4 in EryR
mutants selected in vivo.
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